London, UK, 21 March 2016: Syncona LLP (“Syncona”), a healthcare investment company that supports transformational science with the capital and capability to build standalone businesses, announces the appointment of Hitesh Thakrar as Partner.
Syncona, founded in 2012 as an independent subsidiary of the Wellcome Trust, builds companies based on breakthrough technology with the potential of delivering transformative healthcare products. Syncona’s investments to date have focused on gene therapy, cell therapy and advanced diagnostic technologies.
Martin Murphy, CEO of Syncona commented:
“We are delighted that Hitesh is joining the Syncona team. He brings an exceptional track record in public market investing and will add important capabilities to our team.”
Hitesh Thakrar added:
“I am truly excited at the opportunity presented by Syncona. Over the last 20 years I have invested in multiple cycles of innovation in a number of sectors. I believe that the life sciences sector is entering a phase of substantial innovation that promises to disrupt the healthcare market and deliver great outcomes to patients. Syncona’s approach of backing the leading clinicians and scientists in these emerging areas will place it at the centre of these important changes.”
Hitesh has over 20 years’ experience in successfully investing in global public equity markets in the growth and innovation led sectors. He was a AA rated Fund Manager of the New Star Innovation Fund and more recently was the Portfolio Manager of a top-decile performing Fund, the Global Innovation Fund for a major Sovereign Wealth Fund. He specialised in investing in listed early stage biotechnology and healthcare companies. Hitesh has a BSc in Chemistry from Kings College, London, MBA from Cranfield University and is a CFA charterholder. In 2012 he was awarded a Fellowship in Innovation by the Centre for Science and Policy, part of Cambridge University, UK.
Further information:
Syncona
Martin Murphy
+44 (0) 20 7611 2031
JW Communications
Julia Wilson +44 (0) 781 8430877
juliawilsonuk@gmail.com
Notes for Editors:
About Syncona
Syncona LLP was founded in 2012 and operates as a healthcare investment company, taking an active role in identifying, developing and funding technologies with the potential to significantly impact the healthcare market of the future. Syncona can take the long view when necessary, able to concentrate investment into opportunities as technology is validated. Syncona is a subsidiary of the Wellcome Trust. For further information please visit the Company’s website at: www.synconallp.com
